InvestorsHub Logo
Followers 61
Posts 7517
Boards Moderated 2
Alias Born 02/10/2010

Re: Nanotoday post# 122647

Wednesday, 06/29/2016 11:03:39 AM

Wednesday, June 29, 2016 11:03:39 AM

Post# of 146196
Why? It's still not a bad long-term thing to have in the pipeline and - at present - it doesn't cost much or take up resources that are otherwise available while the labs chew on the HerpesCide drug candidate.

Better tell Seymour to halt the Zika work they're doing.


Smart people can walk & chew gum (aka - multitask),... and NNVC and TheraCour have got a lot of smart warm bodies on staff,...

Stopping on the drug candidate development end - which uses small batch sizes, and different subsets of equipment than does work with more finalized candidates - would be a silly and short-sighted thing for the company to do.

Once HerpesCide is into TOX and/or clinical tests,.... and once FluCide is (again) ready to move forward,....

The next thing in the pipeline could easily be a DengueCide/ZikaCide or general Anti-Flavivirus drug candidate. If they don't work on this in the background in the meantime,... then they can't hit the ground running with it once the other pieces are moving forward.

“The two most powerful warriors are patience and time.”
- Leo Nikolaevich Tolstoy

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NNVC News